ESR1 and breast cancer: BC has distinct pathological subtypes based on the immunohistochemical evaluation of the protein and/or gene expression of ER (estrogen receptor), PR (progesterone receptor), and HER2 receptor, along with the Ki-67 proliferation index [15,16,17,18].